title: Characterization of focal hepatic masses by dynamic contrast-enhanced MR imaging: findings in 311 lesions.
abstract: This study aimed to determine the overall accuracy of known enhancement patterns for the characterization of a large series of focal hepatic masses on dynamic contrast-enhanced magnetic resonance (MR) images. Breath-hold T1-weighted images of the liver acquired before intravenous gadolinium administration and serially over 6-10 min after contrast injection were acquired in < 25 a using FLASH or rapid spin-echo pulse sequences. A total of 311 proven focal hepatic masses in 128 patients were analyzed, including 192 malignant lesions (166 metastases and 26 hepatomas) and 119 benign lesions (48 cavernous hemangiomas, 45 hepatic cysts, and 26 other abnormalities). The lesions were evaluated for a variety of characteristics independently by two reviewers who were blinded to results. Cavernous hemangiomas showed early peripheral nodular enhancement (80% sensitivity and 99% specificity) and hepatic cysts showed no enhancement (100% sensitivity and 95% specificity). Hepatic metastases showed variable, moderate enhancement (47% by one reviewer and 74% by the other). Metastatic lesions from hypervascular primary neoplasms displayed peak enhancement during the hepatic artery dominant (bolus) phase, while other malignant neoplasms showed later peak enhancement (72% sensitivity and 77% specificity). Five metastatic foci with early homogeneous enhancement showed a delayed peripheral washout of contrast (rim sign), while no nonmetastatic foci displayed this finding (3% sensitivity and 100% specificity). Characteristic enhancement patterns of focal hepatic lesions were described in a large series of patients. This study confirms results of previous investigators who have shown that early nodular peripheral enhancement was highly specific for hemangiomas and lack of enhancement was highly specific for hepatic cysts. Hypervascular metastatic foci show earlier peak enhancement than other malignant lesions. Some (2-3%) metastatic lesions display a peripheral washout of contrast on serial images, with 100% specificity.
authors.affiliation: Mallinckrodt Institute of Radiology, St. Louis, MO 63110, USA.
authors.forename: S P
authors.initials: SP
authors.lastname: Quillin
authors.forename: S
authors.initials: S
authors.lastname: Atilla
authors.forename: J J
authors.initials: JJ
authors.lastname: Brown
authors.forename: J A
authors.initials: JA
authors.lastname: Borrello
authors.forename: C Y
authors.initials: CY
authors.lastname: Yu
authors.forename: T K
authors.initials: TK
authors.lastname: Pilgram
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis; D003287:Contrast Media / Q000008:administration & dosage; D003560:Cysts / Q000175:diagnosis; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005682:Gadolinium / Q000008:administration & dosage; D019786:Gadolinium DTPA; D006392:Hemangioma, Cavernous / Q000175:diagnosis; D006499:Hepatic Artery; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008107:Liver Diseases / Q000175:diagnosis; D008113:Liver Neoplasms / Q000098:blood supply / Q000175:diagnosis* / Q000556:secondary; D008279:Magnetic Resonance Imaging / Q000379:methods*; D008297:Male; D008536:Meglumine / Q000008:administration & dosage; D008875:Middle Aged; D009942:Organometallic Compounds / Q000008:administration & dosage; D004369:Pentetic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives; D012119:Respiration; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D016037:Single-Blind Method
chemical_list: D003287:Contrast Media; D004338:Drug Combinations; D009942:Organometallic Compounds; D008536:Meglumine; D004369:Pentetic Acid; D005682:Gadolinium; D019786:Gadolinium DTPA